BACKGROUND: Results from preclinical and observational studies suggest that β-adrenoreceptor inhibition might influence disease progression of melanoma. PATIENTS AND METHODS: Patients ⩾18years with cutaneous melanoma (Breslow thickness >1mm) registered in the Eindhoven Cancer Registry between January 1, 1998 and December 31, 2010, who were also registered with PHARMO record linkage system (RLS), were eligible. Randomly selected patients using β-blockers from PHARMO record linkage system (RLS) matched on age and gender served as a control cohort. Adjusted time-dependent and time-fixed Cox proportional hazard models were employed to estimate the hazard ratio of all-cause mortality. Five-year relative survival rates for all-cause mortality were calculated to estimate disease specific survival. RESULTS: 203 of 709 eligible patients used β-blockers after melanoma diagnosis. The use of β-blockers was not associated with the risk of dying (adjusted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.55-1.24). Neither duration of exposure nor β-blocker dosage showed significant influence on survival. Five-year relative survival for β-blocker users was lower than in non-users amongst melanoma patients (80.9% and 83.7%, respectively) but higher among the β-blocker control group compared to the general population (101.4%). CONCLUSION: Our results do not show a statistically significant impact of β-blocker exposure on overall survival of melanoma patients, regardless of the timing, duration or dosage of β-blocker use.
BACKGROUND: Results from preclinical and observational studies suggest that β-adrenoreceptor inhibition might influence disease progression of melanoma. PATIENTS AND METHODS: Patients ⩾18years with cutaneous melanoma (Breslow thickness >1mm) registered in the Eindhoven Cancer Registry between January 1, 1998 and December 31, 2010, who were also registered with PHARMO record linkage system (RLS), were eligible. Randomly selected patients using β-blockers from PHARMO record linkage system (RLS) matched on age and gender served as a control cohort. Adjusted time-dependent and time-fixed Cox proportional hazard models were employed to estimate the hazard ratio of all-cause mortality. Five-year relative survival rates for all-cause mortality were calculated to estimate disease specific survival. RESULTS: 203 of 709 eligible patients used β-blockers after melanoma diagnosis. The use of β-blockers was not associated with the risk of dying (adjusted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.55-1.24). Neither duration of exposure nor β-blocker dosage showed significant influence on survival. Five-year relative survival for β-blocker users was lower than in non-users amongst melanomapatients (80.9% and 83.7%, respectively) but higher among the β-blocker control group compared to the general population (101.4%). CONCLUSION: Our results do not show a statistically significant impact of β-blocker exposure on overall survival of melanomapatients, regardless of the timing, duration or dosage of β-blocker use.
Authors: S Fazeli Farsani; P C Souverein; J A Overbeek; M M J van der Vorst; C A J Knibbe; R M C Herings; A de Boer; A K Mantel-Teeuwisse Journal: Br J Clin Pharmacol Date: 2015-05-20 Impact factor: 4.335